Discover our new oral solid dose (OSD) development capabilities at our Bend, Oregon site.
The percentage of parenteral drugs approved continues to increase as the overall drug market expands and new therapies for chronic and rare diseases enter the pipeline. In addition to this, swift advancement in biosimilars and biological products is projected to drive the parenteral drugs market growth in the years ahead.
Listen to this on-demand webinar to hear from industry experts, Christy Eatmon and Peter Shapiro.